A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon

Trial Profile

A Phase II/III, Double-Blind, Placebo-Controlled Study of ME2125 in Patients with Parkinson's Disease with Wearing-Off Phenomenon

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Safinamide (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Meiji Seika Pharma
  • Most Recent Events

    • 28 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2018 According to an Eisai Co Ltd media release, based on the results of the study, Meiji plans to submit a marketing authorization application for safinamide in Japan during 2018.
    • 01 Feb 2018 Primary endpoint has been met. (on time), as reported in an Eisai Co Ltd media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top